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Treatment of large segmental bone defects remains an unsolved clinical challenge, despite a wide array of
existing bone graft materials. This project was designed to rapidly assess and compare promising biodegradable
osteoconductive scaffolds for use in the systematic development of new bone regeneration methodologies that
combine scaffolds, sources of osteogenic cells, and bioactive scaffold modifications. Promising biomaterials and
scaffold fabrication methods were identified in laboratories at Rutgers, MIT, Integra Life Sciences, and Mayo
Clinic. Scaffolds were fabricated from various materials, including poly(L-lactide-co-glycolide) (PLGA), poly(L-
lactide-co-e-caprolactone) (PLCL), tyrosine-derived polycarbonate (TyrPC), and poly(propylene fumarate) (PPF).
Highly porous three-dimensional (3D) scaffolds were fabricated by 3D printing, laser stereolithography, or
solvent casting followed by porogen leaching. The canine femoral multi-defect model was used to systematically
compare scaffold performance and enable selection of the most promising substrate(s) on which to add cell
sourcing options and bioactive surface modifications. Mineralized cancellous allograft (MCA) was used to
provide a comparative reference to the current clinical standard for osteoconductive scaffolds. Percent bone
volume within the defect was assessed 4 weeks after implantation using both MicroCT and limited histomor-
phometry. Bone formed at the periphery of all scaffolds with varying levels of radial ingrowth. MCA produced a
rapid and advanced stage of bone formation and remodeling throughout the defect in 4 weeks, greatly exceeding
the performance of all polymer scaffolds. Two scaffold constructs, TyrPCPL/TCP and PPF4SLA/HAPLGA Dip,
proved to be significantly better than alternative PLGA and PLCL scaffolds, justifying further development.
MCA remains the current standard for osteoconductive scaffolds.
Introduction
This project was designed to rapidly assess and com-pare promising biodegradable osteoconductive scaffold
compositions without bioactive molecules for the treatment
of critical size bone defects. This study describes the first step
in a systematic effort to develop new bone regeneration
methods for treatment of large segmental bone defects that
combine scaffolds, sources of osteogenic cells, and bioactive
scaffold modifications.
In both the military and civilian population, treatment of
large segmental bone defects remains an unsolved clinical
challenge, despite a wide array of existing bone graft mate-
rials. Extremity injuries represent 58%–88% of all traumatic
injuries in United States armed conflicts.1 These fractures are
frequently comminuted, complicated by extensive soft-tissue
loss, and have segmental bone defects ranging from 0 to
20 cm. The biological challenge of bone regeneration is made
more complex by associated regional soft tissue loss, reduced
local vascularity, and regional scarring that follow both the
initial injury and any secondary infections that occur. Bone
defects are most frequent in the tibia; however, defects in the
femur, humerus, radius, ulna, and mandible are also com-
mon. Clinical success in regenerating bone in these defects
can be achieved using one or more of several current meth-
ods and materials. However, success is variable, even in the
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hands of highly skilled and experienced surgeons. Moreover,
even when success is achieved, the time necessary to achieve
it is often prolonged and characterized by multiple proce-
dures and complications.
Effective bone tissue engineering in the setting of a seg-
mental bone defect requires both an awareness and rational
management of multiple factors. These include the use of
osteoconductive scaffolds, osteogenic cells, osteoinductive
and osteopromotive stimuli, and the provision of both an
appropriate biomechanical environment and mass transport
environment. Each of the critical variables contributes, in
combination with the others, to success or failure.2 Osteo-
conductive scaffolds, the focus of this work, may serve
multiple functions, providing (1) a space holder that pre-
vents encroachment of surrounding tissues into the graft site;
(2) a three-dimensional (3D) lattice or surface that facilitates
the attachment, survival, migration, proliferation, and dif-
ferentiation of stem cells and progenitor cells promoting the
distribution of a bone healing response throughout the
grafted volume; (3) a vehicle for delivery of cells into a graft
site, facilitating their retention and distribution throughout
the region where new tissue is desired; and/or (4) a vehicle
for presentation or delivery of bioactive agents.3–6
Autogenous cancellous bone (ACB) frequently harvested
from the iliac crest is currently considered to be the most
effective bone graft material for bone defects. ACB provi-
des a degradable osteoconductive scaffold in the form of
mineralized trabecular bone that will undergo osteoclast-
mediated remodeling and replacement with native bone.
This remodeling may also release bioactive factors that
provide osteoinductive and osteopromotive stimuli in the
bone defect site. In addition, ACB includes the transplanta-
tion of a population of osteogenic cells that are resident
on the trabecular surface and in the marrow space. However,
the availability of autograft material is limited, and often
insufficient for large defects. Moreover, the harvesting of
ACB is associated with blood loss, pain, scarring, and the
potential for infection and secondary disability.
Human bone allograft, processed from cadaveric donors,
has been the preferred osteoconductive matrix when suffi-
cient ACB is either unavailable or is contraindicated due to
associated morbidity. Allograft is available in any volume
that is needed. It is also available in many formulations
(blocks, chips, fibers, powders) that can be customized for
specific clinical settings. However, by far, the most common
formulation of allograft for bone grafting procedures is
mineralized cancellous allograft (MCA) (commonly referred
to as ‘‘chips’’ or ‘‘croutons’’).
A broad range of alternative scaffolds is already available
for clinical use, and many new scaffolds are under devel-
opment. Differences between scaffolds can be generally cat-
egorized into six domains: bulk material, 3D architecture and
porosity, surface chemistry, mechanical properties, initial
scaffold environment (osmolarity, pH), and late scaffold
environment (degradation characteristics). Each domain has
important implications for both the biological response of
local tissues to a scaffold and for a given scaffold’s utility in
transplanting or supporting local stem cells and progenitors.2
Clinically available scaffolds are made from a broad range
of bulk materials. These include tissue-derived materials
(e.g., allograft bone matrix, skin, intestinal submucosa), bio-
logical polymers (e.g., collagen, hyaluronan, fibrin, alginate),
ceramics or mineral-based matrices (e.g., tricalcium phos-
phate, hydroxyapatite, calcium sulfate), metals (e.g., tita-
nium, tantalum, and other alloys), or composites of two or
more materials.2,7,8 A variety of synthetic water-insoluble
polymers are also being adapted or developed. These in-
clude, but are not limited to, poly(lactide), tyrosine-derived
polycarbonates (TyrPCs),9–12 poly(caprolactone), poly(pro-
pylene fumarate) (PPF),13–15 and synthetic hydrogels [e.g.,
poly(ethylene oxide)based materials].16–18 The potential ad-
vantage of these alternative synthetic scaffolds over allograft
is an increase in reproducibility, a reduction in production
cost, the potential for custom fabrication to fit the shape of
defined defects, and the capacity to be used as a substrate
material. The substrate material can then undergo systematic
improvement through changes in its architecture, surface
chemistry, mechanical and degradation properties, and local
delivery of drugs or bioactive agents.
The work described in this report was designed to (1)
rapidly assess and compare several promising osteoconduc-
tive biodegradable scaffolds, (2) compare their performance to
the current standard for osteoconductive materials (MCA),
and (3) in doing so, identify one or more scaffold constructs
worthy of further optimization as delivery vehicles for use in
combination with sources of osteogenic cells and/or presen-
tation or delivery of bioactive agents.
Materials and Methods
Implant materials
Four biomaterials laboratories were recruited into the
Limb Salvage Program in the Rutgers-Cleveland Clinic
Consortium of the Armed Forces Institute for Regenerative
Medicine (AFIRM). The overall aim of the AFIRM limb sal-
vage program is the rapid development of new therapeutic
strategies that specifically target the needs of wounded
warriors and victims of civilian trauma who face the chal-
lenge of large segmental bone defects. The strategy proposed
here was to systematically and competitively assess each
laboratory’s best available degradable synthetic biomaterial
scaffolds for bone regeneration, comparing their perfor-
mance to each other and against current clinical standards. In
doing so, one or more scaffold substrates would be selected
for further development as a carrier (a delivery system) for
osteogenic cells and bioactive agents. Participating labora-
tories and investigators included The New Jersey Center for
Biomaterials at Rutgers University (Lab Director Joachim
Kohn, PhD), the Mayo Clinic Tissue Engineering and
Polymeric Biomaterials Laboratory (Lab Director Michael
Yaszemski, MD, PhD), the Griffith Lab Massachusetts In-
stitute of Technology (Lab Director Linda Griffith, PhD), and
Therics, LLC (formerly of the Theken family of companies,
Akron, OH). Therics and MIT provided both materials for
evaluation, and also made the fabrication strategy of three-
dimensional printing (3DP) available to other collabora-
tors.18–21 Each laboratory had a history of biomaterials with
efficacy in small animals.9–12,14,22–28
The tested scaffolds are outlined in Table 1, which provi-
des a brief summary of the bulk material, fabrication process,
pore geometry, use of calcium containing components, and
method of sterilization used in each case.
The bulk polymer materials that were evaluated included
70:30 Poly(L-lactide-co-e-caprolactone) (PLCL; Boehringer
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Ingelheim, Petersburg, VA); 82:18 Poly(L-lactide-co-glycolide)
(PLGA; Boehringer Ingelheim)29; Tyrosine-derived poly-
carbonate (Kohn Laboratory, Rutgers University); and PPF
(Yaszemski Lab, Mayo Clinic).30–33 Supplementary data de-
scribing more details on the PPF material synthesis and
fabrication is available online at www.liebertpub.com/tea.
All scaffolds were manufactured using previously defined
methods into cylinders with dimensions of 0.99 cm diameter
and 1.5 cm height. The methods used previously published
procedures for fabrication of 3D scaffolds: 3DP,28,29,34 ste-
reolithography (SLA),13,35 and PL.12 Figure 1 provides rep-
resentative images illustrating the variation in structure that
was provided using these methods.
Experiments were performed in the order presented. Data
from prior experiments were used by each laboratory to
guide subsequent modifications of scaffold fabrication and
composition. All but three polymeric scaffolds contained a
calcium component incorporated into the polymer material.
In Experiments 1, 2, and 5, b tri-calcium phosphate (b-TCP)
granules with size range of 45–106 mm and a porosity of 65%
were used (Therics, LLC, Akron, OH). In Experiments 4 and
6, nanocrystals of hydroxyapatite with an average size of
100 nm (range = 20–550 nm) (nanohydroxyapatite; Berkeley
Advanced Biomaterials, Berkeley, CA) and b-TCP coatings
were applied on PPF scaffolds. In Experiment 7, porogen
leached scaffolds with a porosity of *85%–95% were used.
Calcium chloride (Sigma Aldrich, St. Louis, MO) was added
through saturation of scaffolds with a 10% calcium chloride
solution, or b-TCP granules with a size range of 45–106 mm
(Therics, LLC) were included during the porogen leaching
(PL) fabrication process.
MCA bone matrix (canine) was utilized as the reference
standard for current clinical practice. MCA was prepared
and packaged by the Musculoskeletal Transplant Founda-
tion (MTF; Edison, NJ) using canine bones from the proximal
humerus, proximal tibia, and contralateral proximal femur.
Donor bone was sterilely harvested from canine subjects
used in prior experiments following euthanasia. Harvest,
shipping at Cleveland Clinic, and processing at MTF were
performed using standardized methods that are in common
use for preparation of commercially available mineralized
cancellous bone matrix consistent with clinical guidelines
established by the American Association of Tissue Banks.
Cuboidal chips were prepared with a dimension of roughly
3· 3· 3mm to enable uniform packing of 20–25 chips to fill
each femoral defect site. Sterile processing was maintained
throughout with standard confirmatory cultures. No termi-
nal sterilization was used.
Animals
This study was conducted with approval from the Cle-
veland Clinic Institutional Animal Care and Use Committee
(IACUC), and the Animal Care and Use Review Office
(ACURO) of U.S. Army Medical Research and Materiel
Command (MRMC). Study animals were cared for in ac-
cordance with the principles of the Guide for the Care and Use
of Laboratory Animals.36
FIG. 1. Implanted scaffolds: (A) PLCL/TCP3DP, (B) TyrPCPL, (C) PPF2SLA, and (D) MCA chips (*3· 3mm). Horizontal
scale on lower images is*4mm. (SEM image of the TyrPCPL scaffold was provided by Joachim Kohn, New Jersey Center for
Biomaterials, Rutgers University.) 3DP, three-dimensional printing; MCA, mineralized cancellous allograft; PL, porogen
leaching; PLCL, poly(L-lactide-co-e-caprolactone); PPF, poly(propylene fumarate); SLA, stereolithography; TCP, tri-calcium
phosphate; TyrPC, tyrosine-derived polycarbonate.
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Eighty-five adult purposely breed female and male coon-
hounds (34.3 – 4.2 kg, age 2.5 years– 01 months [range 1–5
years]) were used.
Canine femoral multi-defect model
The canine femoral multi-defect (CFMD) model 37,38 was
used for these studies. The CFMD model provides four 10-
mm-diameter and 15-mm-long defects for assessment in each
subject. These defects are placed in the lateral cortex of the
proximal femur. Each defect site is separated by a minimum
of 1.5 cm of normal bone and marrow, so that the sites do not
interact. The availability of data from four sites in each subject
enables comparison of two to four materials while controlling
for variation between subjects. The defects are designed to be
of sufficient size to create a biological environment in which
the interior of the defect is characterized by profound hypoxia,
a key feature of large clinical defects that is not modeled in
small animal defects. Bone formation and revascularization
within the defect occur through a process of ingrowth that has
a radially oriented outside-in pattern, which can be readily
measured and characterized using microcomputed tomogra-
phy (MicroCT) and histological methods. As a result, the ex-
tent to which a bone healing response progresses into the
center of these defects provides an objective comparison of the
efficacy of the implanted scaffold materials.
Experimental design
From March 2008 to December 2010, a series of eight ex-
periments were performed between paired materials. The
experiments are outlined in Table 1. Each experiment utilized
10 subjects. In each experiment, the two scaffolds (e.g., ‘‘A’’
and ‘‘B’’) were randomly assigned to either an ‘‘ABBA’’
configuration (five dogs) or a ‘‘BAAB’’ configuration (five
dogs) to control for possible site or proximity effects.
Outcome assessment 4 weeks after implantation was se-
lected for two reasons: (1) prior experience using ACB and
allograft cancellous bone in this model has demonstrated the
potential to achieve robust bone formation and even an ad-
vanced state of intramedullary (IM) remodeling in the CFMD
model as early as 4 weeks, and (2) those scaffolds that are most
effective in initiating rapid onset of bone formation and in-
growth are, we feel, the same scaffolds that are likely to achieve
reliable outcomes that represent an advance over existing
therapies. Therefore, assessment at later time points might be
too late to detect clinically important differences in the rate of
onset and extent of new bone formation between scaffolds.
Operative procedure
A fentanyl transdermal patch (100mg/h) was applied the
day before the procedure. Penicillin G (1.2 MillU IM) and
atropine (0.02mg/lb IM) were given on the morning of sur-
gery. General anesthesia was initiated using pentothal
(20mg/kg IV) followed by intubation and closed isoflurane
(0.5%–3%) inhalation. The left hind limb was shaved, prep-
ped, and draped in a sterile fashion. In two cases, Experiments
5 and 8, a single scaffold material was tested with and without
bone marrow clot (BMC). In these cases, following the in-
duction of anesthesia, a 2 cc aspirate of bone marrow was
harvested from the left proximal humerus using standard
clinical technique without an anticoagulant and allowed to
clot.2,39,40 A 10 cm incision was made on the lateral aspect of
the thigh, beginning 4 cm distal to the greater trochanter of the
femur. The biceps muscle was then reflected posteriorly and
the vastus lateralis was elevated anteriorly in an extra-
periosteal plane to expose the anterolateral aspect of the fe-
mur. A custom drill guide (Fig. 2) was fixed to the femur
using two 3.5-mm-diameter cortical screws (Synthes, Paoli,
PA). Four identical 1.0-cm-diameter and 1.5-cm-long cylin-
drical defects were then created by sequential use of a circular
starting trochar, a pointed drill, and a flat finishing drill. A 1.0-
cm-diameter by 1.5-cm-long stainless steel spacer was placed
in each defect temporarily to allow hemostasis to be achieved
without formation of a clot of wound blood in the space that
was preserved for the scaffold. The appropriate scaffolds for
the particular experiment were then placed in each defect. The
graft sites were protected mechanically using a stainless steel
plate that was fixed to the femur using two screws placed into
the screw holes created for initial fixation of the drill guide.
The vastus lateralis was then replaced over the defect sites and
under the biceps in an anatomic position. The wound was
closed using 0 vicryl sutures to re-approximate the deep fas-
cia, followed by 2–0 vicryl sutures in subcutaneous and sub-
cuticular layers, and then staples in the skin.
Animal care
Animals were allowed free access to food and water and
returned to full weight bearing with daily exercise. Agitation
in the early postoperative period was managed using ace-
promazine (0.1mg/kg SQ). Postoperative pain was managed
with the transdermal fentanyl (100 mg/h) patch for 3–6 days,
supplemented by Buprenorphine as needed.
Euthanasia was performed 4 weeks after implantation
using Beuthanasia solution (5mL/5 kg IV; Merck Animal
FIG. 2. (A) Drill guide in
position on the lateral surface
of the proximal femur. (B)
Defect sites before
implantation of scaffolds.
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Health, Summit, NJ). The plate spanning the defects was
removed. The femur was explanted and cleared of adhering
tissue. Individual defect sites were separated using a band
saw and fixed in 10% neutral buffered formalin. After 48 h,
the solution was replaced with 70% ethanol to prevent de-
mineralization. MicroCT images were obtained of each graft
site prior to processing for histological assessment.
MicroCT processing and analysis
Quantitative assessment of each graft site was performed
using MicroCT and 3D segmental image postprocessing (Fig.
3). Scanning was done with an eXplore Locus MicroCT
scanner (GE Healthcare, Milwaukee, WI) at 45 micron reso-
lution, 360 projections acquired every degree of rotation. The
system was operated at 80 kV, 500mA, with an exposure time
of 500ms per individual projection. A dark-field (X-ray beam
turned off), a bright field (X-ray beam turned on with no
sample in beam), and density phantom (hydroxyapatite,
solid water, air) image was taken at the end of each imaging
session for correction of the X-ray projection data (dark- and
bright-field normalization, ring artifact reduction, and CT
attenuation to Hounsfield Unit conversion during projection
reconstruction). Each defect was positioned with the cranial-
caudal axis (i.e., the cross-sectional plane of the cylindrical
specimen) parallel to the direction of table travel.
Regions of bone formation within the defect site were
identified based on calibrated Hounsfield Units (HU) re-
presenting native trabecular bone (1000 – 100 HU) within
each sample to provide reproducible thresholding across all
specimens by an operator who was blinded with respect to
the material being assessed. A 3D cylindrical defect template,
10mm in diameter and 15mm in length size, was manually
positioned to define the boundaries of the defect site using
the circular introitus and marks from the flat finishing drill
on the opposite cortex as fiduciary guides (Fig. 3). Voxels
within the defect site above the threshold value for trabec-
ular bone were identified and segmented as new bone. Per-
cent bone volume (% BV) was measured by determining the
fraction of bone voxels within the defect site volume. The
pattern and density of bone formation in each defect was
plotted for visualization by projecting % BV data as a 2D
contour plot using a color range of 0%–30% BV. The X-axis
indicates radial position from the center of the defect to the
edge (range 0–5mm), and the Y-axis represents vertical po-
sition within the defect from the bottom to the opening at the
lateral cortex (range 0–15). Data for the 20 samples of each
scaffold that were evaluated in each paired experiment were
FIG. 3. Micro computed tomography processing technique. (A) The 3D defect volume is defined using a standard 10-mm-
diameter · 15-mm-long cylinder. Following segmentation, bone volume (BV) data are mapped onto a color 2D contour plot
using a scale from 0% to 30% BV. (B) The defect site is divided for analysis into regions for analysis. The pericortical (PC)
region and the intramedullary (IM) region are defined based on vertical position from the bottom of the defect. Three regions
of depth are defined based on radial distance from the center in millimeters: center (C)= 0.25–1.75mm, middle (M) = 1.75–
3.25mm, and outer (O) = 3.25–4.75mm.
EVALUATION OF OSTEOCONDUCTIVE SCAFFOLDS IN CFMD MODEL 639
combined to project the mean % BV for each scaffold. For
analysis, the defect sites were subdivided into regions of
interest based on differences in local tissue environment. The
pericortical (PC) region (between 8 and 12mm from the
bottom of the grafted site) represents the region of the graft
site that is adjacent to the cortex, where the contribution of
cells from periosteum, cortex, and endosteum may contrib-
ute to new bone formation. In contrast, the IM region (be-
tween 3 and 7mm from the bottom of the grafted site) is
separated, by several millimeters, from the endosteal source
of osteogenic cells and bounded only by cells from the
marrow cavity (See Fig. 3). The PC and IM regions are fur-
ther divided into a center, middle, and outer region based on
the radial position within the defect site. The scaffold per-
formance in the center-most region of the defect was con-
sidered to be the most discriminating with respect to likely
efficacy in larger defects, and therefore serves as the primary
outcome parameter for comparison between scaffolds.
To minimize the confounding effects of variation in % BV
unrelated to scaffold performance, the region of interest for
analysis of data within the defect sites was carefully defined.
Variation due to nonradially oriented boundary effects at the
top soft tissue interface and the bottom trabecular bone inter-
facewasminimized by eliminating the top and bottom3mmof
each defect fromanalysis. The axial center (radius= 0–0.25mm)
was removed from analysis due to the vanishingly small
sampling volume that is assessed as one approaches a radius of
zero. This creates high variability in data near the axial center.
Finally, data from the very edge of each defect (radius= 4.75–
5.0mm) were also removed to minimize the probability of
random inclusion of existing cortex in the analysis of the PC
region resulting from the positioning of the defect template.
Histology analysis
Histology was used as a secondary qualitative outcome
parameter and primarily as a means of (1) screening for evi-
dence of local inflammation that might be induced by a par-
ticular implant, (2) provisional assessment of the rate of bulk
degradation taking place for a given scaffold (both bulk poly-
mer and any remaining calcium containing component, (3)
validation of the % BV data obtained using MicroCT, and (4)
screening for important differences in the nature and quality of
bone and soft tissue remodeling between different scaffolds.
Two defect sites for each material were assessed by histomor-
phometry in each experiment, representing a subsampling of
10% for each material. All samples were processed and ana-
lyzed in the Bone Histomorphometry Laboratory at the Mayo
Clinic using undecalcified processing. Each specimen was de-
hydrated, embedded in methacrylate, and polymerized. Sec-
tions with 5-mm thickness were cut using a Leica RM 2265
microtome and stained using both Goldner’s Trichrome, and
hematoxylin and eosin (H&E). The Goldner’s trichrome-
stained sections were scanned using a NanoZoomer Digital
Pathology System (Hamamatsu, Bridgewater, NJ) and ana-
lyzed using the software package IHC score (Bacus Labs,
Lombard, IL) to measure the percent of bone volume, the
percent of nonbone cellular matrix, the percent of residual
implant, and nontissue or implant spaces or artifacts. Because
the IHC score does not distinguish between remaining un-
resorbed allograft and newly formed bone tissue, additional
manual analysis was performed on samples of containing
MCA scaffold using the OsteoMeasure system (OsteoMetrics,
Decatur, GA) to estimate the relative contribution of new bone
versus residual allograft to the total bone measurement pro-
vided by MicroCT. In order to provide systematic and repre-
sentative sampling, a contiguous series of 20· magnification
fields were examined extending in a transaxial plane across the
defect site through themid-portion of the PC region. Regions of
cellular new bone and acellular residual allograft were traced.
Total bone areawas expressed as a percentage of the tissue area
measured. The relative area of new bone and residual allograft
was expressed as a percentage of the total bone area. Scaffolds
containing TCP and HA when implanted were also examined
to look for evidence of residual TCP or HA that could added
mineral density and result in an artifactual increase the overall
% BV estimates.
Statistical analysis
Statistical analysis was performed on individual experi-
ments as they were completed. The mean % BV in the center,
middle, and outer depths of the PC and IM regions of each
defect was used as response variables. Due to extreme
skewness (Fig. 4), the data were transformed using the log
function. The analyses were performed using a mixed effect
analysis of variance (ANOVA) that included scaffold, posi-
tion, region, and distance to the center. Interactions were
tested. Dog was included as a random effect.
The analysis of the combined data from the eight experi-
ments was performed using SAS software (SAS, Cary,
NC) and JMP 9.0.0 software (SAS). The analysis was done
with a similar mixed effect ANOVA model. The Tukey-
Kramer method for multiple paired comparisons was used to
separate the means for the scaffolds. The significance level
was set at p = 0.05.
Results
Animal care
Nine of the 85 canine subjects (10%) developed a fracture
of the femur resulting in immediate euthanasia and exclusion
from further analysis. There were no other complications.
MicroCT % BV data
Two-dimensional contour plots of % BV are presented in
Figure 5, illustrating the pattern, distribution, and density of
bone formation for all scaffolds. As in prior assessments
using the CFMD, the highest percent bone volume was
found nearest the periphery of the defect, with variable levels
of penetration into the middle and central regions. In addi-
tion, in all cases, % BV was highest in the PC region of the
defect, and lower in the IM region. These images also illus-
trate that the bone formation realized after implantation of
MCA far exceeded that of all other scaffold constructs.
In Figure 6, the % BV data for all scaffold materials are
presented as 2D plots that illustrate the quantitative change in
% BV relative to depth within the defect. Data for the overall
defect, the PC region alone, and the IM region alone are pre-
sented separately. These plots illustrate that marked differ-
ences in % BV were seen between scaffolds in the outer,
middle, and center region of the defect site. Bone formation
was greatest at the periphery of the defect (outer region) and
decreased as one progressed to the middle and center regions
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FIG. 4. Percent bone volume (% BV) raw data distribution for the overall defect site is extremely skewed toward low values
for all scaffolds except MCA. This was adjusted to enable parametric analysis by applying the logarithm transformation.
FIG. 5. Two-dimensional contour plots of bone volume percent using color map ranging from 0% (purple) to 30% (red).
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in all scaffolds. % BV was consistently two- to threefold greater
in the PC region than in the IM region at each region of depth.
The MCA scaffold resulted in a four- to sixfold greater %
BV than any of the polymer scaffolds. When MCA was used,
the arithmetic mean % BV in the PC region was 40% or
greater all the way to the center of the defect. In the most
clinically relevant center area (radial position 0.25–1.75mm),
the mean % BV for one polymer scaffold, TyrPCPL/TCP
tended to rise above the other scaffolds, approaching an
arithmetic mean of 5%.
The histogram shown in Figure 6 plots the distribution of %
BV data for all implants using each material, and the effect of
the log transformation that was performed to improve nor-
mality. Table 2 presents the result of the Tukey-Kramer
analysis that compared scaffolds based on % BV in the overall
defect region (radial range 0.25–4.75mm and depth range 3–
12mm). Performance differed significantly from one scaffold
to another ( p< 0.0001). Table 3 presents the result of the
Tukey-Kramer analysis that compared scaffolds in the most
biologically challenging center (radial position 0.25–1.75mm)
of the IM region. MCA displayed significantly higher % BV
than any polymer scaffold tested ( p< 0.0001) in both analyses.
The geometric mean % BV for MCA was 34.6% in the
overall defect region and 19.5% in the center IM region. The
geometric mean % BV for the best performing polymer
scaffold, TyrPCPL/TCP, was 3.00% in the overall defect re-
gion and 1.11% in the center IM region. The geometric mean
% BV for the next highest performing polymer scaffold,
PPF4SLA/HAPLGA Dip, was 1.32% and 0.96% in the overall
defect and center IM regions, respectively.
The TyrPCPL/TCP and PPF4SLA/HAPLGA Dip scaffolds
were statistically superior to all other polymer scaffolds when
FIG. 6. Percent bone volume (% BV) plotted versus radial position for (A) the entire defect volume, (B) the PC region, and
(C) the IM region. BMC, bone marrow clot.
FIG. 7. Undecalcified histology: Representative images for selected scaffold constructs stained using Goldner’s Trichrome.
Magnification at 1· , 5 · , 10 · . The black square box indicates the region of defect where the 5 · magnification is presented.
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compared based on % BV in the overall defect region (both
scaffolds are in Group B in Table 2) and in the center IM
region (both scaffolds are not in Group D in Table 3). How-
ever, TyrPCPL/TCP and PPF4SLA/HAPLGA Dip scaffolds were
not statistically different from each other with respect to % BV
(both are always in the same group in Tables 2 and 3).
In the two settings where the MCA and PLCL/TCP3DP
scaffolds were tested with and without a BMC, there was no
evidence that the addition of BMC changed the biological
performance of the scaffold with respect to % BV.
Histology
Representative histology images are provided for each
scaffold material in Figures 7–9. New tissue formation oc-
curred with little evidence of inflammation and no evidence
of infection.
Defects grafted with MCA were found to have bridging
bone across the PC region. Active osteoclastic resorption of
residual allograft was seen throughout the samples, with
bone formation on all allograft surfaces. Unmineralized os-
teoid was thicker and covered more bone surface in the PC
region, suggesting more active bone formation in the PC
region than in the IM region. Numerous vascular sinusoids
and thin-walled vessels were observed. H&E-stained sec-
tions showed no evidence of inflammation in response to
MCA, nor any evidence of infection. Histomorphometry of
the two MCA-grafted sites examined showed that a mean of
71% of the bone tissue present in the defect site represented
new bone formation, while 29% represented residual un-
resorbed MCA matrix. The residual MCA matrix occupied a
mean of 13% of the total defect area.
TyrPCPL/TCP demonstrated bone formation that was
most extensive in the PC region and appeared to originate
Table 3. Group Separation Table Obtained by Tukey-Kramer Method Analysis
in the Intramedullary Center Defect Region
Groupsa Mean (log) Geometric mean (% BV)
MCA A - 1.63 19.52
MCA +BMC A - 1.73 17.96
TyrPCPL/TCP B - 4.50 1.11
PPF4SLA/HAPLGA Dip B C - 4.65 0.96
PPF2SLA/HAPLGA Dip B C D - 4.72 0.89
TyrPC/TCP3DP B C D - 5.60 0.37
PLCL/TCP3DP B C D E - 6.04 0.24
PLGA/TCP3DP B C D E - 6.20 0.20
TyrPCPL B C D E F - 6.32 0.18
PLCL/TCP3DP +BMC B C D E F - 6.59 0.14
TyrPCPL/CaCI2 C D E F - 6.97 0.09
PLCL/TCP3DP D E F - 6.98 0.09
PPF2SLA/HAPLGA Spray E F - 7.98 0.03
PPF2SLA/TCPPLGA Spray E F - 8.05 0.03
TyrPC3DP E F - 8.24 0.03
TyrPC3DP F - 8.62 0.02
aScaffold formulations that are designated by the same letter group are statistically not different from each other, but are statistically
different from scaffolds in nonoverlapping groups. The formulations labeled ‘‘A’’ had greater % bone volume than all other scaffolds.
Table 2. Group Separation Table Obtained by Tukey-Kramer Method Analysis in the Overall Defect Region
Groupsa Mean (log) Geometric mean (% BV)
MCA A - 1.06 34.64
MCA +BMC A - 1.15 31.65
TyrPCPL/TCP B - 3.51 3.00
PPF4SLA/HAPLGA Dip B C - 4.33 1.32
PPF2SLA/HAPLGA Dip C - 4.59 1.02
TyrPCPL/CaCI2 C - 4.68 0.93
PLCL/TCP3DP C - 4.68 0.93
TyrPC/TCP3DP C - 4.73 0.88
PLGA/TCP3DP C - 4.73 0.88
PLCL/TCP3DP +BMC C D - 4.74 0.88
TyrPCPL C D - 4.89 0.75
PLCL/TCP3DP C D E - 5.00 0.67
PPF2SLA/TCPPLGA Spray D E F - 5.76 0.32
PPF2SLA/HAPLGA Spray E F - 5.91 0.27
TyrPC3DP F - 6.22 0.20
TyrPC3DP F - 6.71 0.12
aScaffold formulations that are designated by the same letter group are statistically not different from each other, but are statistically
different from scaffolds in nonoverlapping groups. The formulations labeled ‘‘A’’ had greater % bone volume than all other scaffolds.
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from the periosteal, cortical, and endosteal surfaces. Active
bone formation was observed, with new mineralized bone
containing a high density of osteocytes and cuboidal osteo-
blasts. Active osteoclasts eroded the bone surface. The scaf-
fold had degraded substantially and was no longer
identifiable as an organized structure. Residual scaffold
material was found to occupy 31% of the defect area. Regions
of residual scaffold were frequently associated with a local
fibrous tissue reaction without evidence of acute inflamma-
tion. Residual TCP may have added mineral density that
slightly increased the overall % BV estimate, but was not
considered to represent a major source of error.
The bone ingrowth in defects grafted with TyrPCPL/CaCl2
was distributed throughout the PC and IM regions. There
FIG. 8. Higher magnification of MCA samples stained with Goldner’s Trichrome stain.
FIG. 9. Example of histology slides for TyrPCPL/TCP and PPF2SLA/TCPPLGA spray samples stained with Goldner’s
Trichrome stain revealing that trabecular bone formation is present and can penetrate deeply into the scaffold constructs in
some areas. In the case of the PPF material, no significant resorption is seen and bone formation is most prominent in the
pores of the scaffold within the PC region of the defect. In the case of the Tyr-PC scaffold, significant degradation of the
scaffold is evident, and trabecular bone formation on the right side of the defect is seen penetrating into the deeper portion of
the defect in some areas, while in other areas left side of the defect demonstrate a reactive fibrous tissue response.
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was no evidence of residual local toxicity from the initial
acid and hyperosmolar environment expected with CaCl2
delivery. Again, residual polymer/scaffold was present in
31% of the defect area. New bone formation was evident
with active secretory osteoblasts, osteoclastic resorption, and
a high density of osteocytes in the new bone.
PPF2SLA scaffolds with TCP +PLGA or with HA +PLGA
spray coatings showed that the PPF polymer scaffold re-
mained intact as an organized structure at 4 weeks. Active
bone formation was observed, with new mineralized bone
containing a high density of osteocytes and cuboidal osteo-
blasts and active remodeling. Residual polymer occupied
*60% of the defect region. The histology suggested that
the HA +PLGA surface coating had delaminated from the
polymer surface and migrated into adjacent tissue within
the defect. New bone formation occurred in the scaffold
macropores, often on the surface of the PPF scaffold, and was
most extensive in the PC defect region.
PLCL/TCP3DP samples showed bone ingrowth at the
edge of the defect area, predominantly from the cortical
and endosteal surface. The PLCL/TCP3DP scaffolds had de-
graded substantially and no longer had an organized struc-
ture. The area occupied by unresorbed polymer was *36%
of the defect.
Discussion
This work was undertaken with the goal of developing
improved therapies for large segmental post-traumatic de-
fects of bone by rapid assessment and comparison of several
promising osteoconductive degradable polymer scaffolds.
The performance of the polymeric scaffolds was compared to
that of the current standard for osteoconductive materials
(MCA), with the expectation of identifying one or more
scaffold constructs that were worthy of further optimization
in combination with sources of osteogenic cells and/or de-
livery of bioactive agents. These goals were met.
There are over 50 current products that are marketed for
clinical use as bone void fillers. These products have received
FDA clearance through the 510K mechanism based on their
substantial equivalence to the performance of the predicate
standard of MCA bone, which remains the most widely used
osteoconductive bone graft material. The initial hope and
expectation of this work was that one or more of the avail-
able formulations of polymer scaffolds would meet or exceed
the performance of MCA. The data presented here demon-
strate that the performance of the polymer scaffolds that
have been tested thus far fall short of that expectation. MCA
exceeded the performance of all polymer scaffolds, and re-
mains the gold standard among osteoconductive bone scaf-
fold materials for future comparisons.
While MCA remains the standard to beat, it must be
pointed out that not all allograft materials are equal. The
potential for variation in performance is one of the potential
limitations of allograft as a therapeutic agent for bone re-
generation. Different formulations and processing methods
can change the biological performance of allograft. Even
when the same processing methods are used, efficacy can
vary between batches and/or donors. As a result, most
providers of allograft bone, in addition to testing sterility,
also perform biochemical and biological assays on the final
allograft product to confirm consistency in potency and
performance. These tests may include biochemical assays to
measure BMP-2 content, in vitro assay of the response of cells
to allograft materials, or in vivo assays of biocompatibility or
osteoinductivity.41–46 Ongoing efforts to refine the formula-
tion of allograft-derived scaffold materials through proces-
sing methods will continue to advance the reproducibility
and efficacy of allograft scaffolds, customization of formu-
lations for specific applications and their specialized use as
delivery systems in combination with cells and bioactive
materials. That said, the performance of allograft in these
studies can be considered to be representative of the ex-
pected clinical performance of MCA allograft. The proces-
sing methods that were used are common standards in the
industry. Two separate donors were used in grafting the 10
study subjects in Experiment 8. There was no difference in
performance between bones derived from these two donors.
Despite the ongoing limitations of the polymer scaffold
formulations tested here, the process of utilizing the CFMD
model as a system for objective comparison of performance
between scaffolds was a success. Significant differences were
found between polymer scaffolds, and these observations
can now be used to guide ongoing modifications and opti-
mization of the design and use of polymer scaffold con-
structs. These data, in addition to prior experience,39,47
demonstrate that the CFMD model system is a robust and
sensitive system with which to make objective comparisons
between materials. The CFMD model allows these compar-
isons to be made in a rapid and efficient manner (only 4
weeks) using a large animal system, in a defect of clinically
relevant size. By collecting four data points from each ani-
mal, the CFMD model maximizes the value of each subject
and minimizes the number of subjects that are needed to
provide sufficient power for comparisons. Moreover, in ad-
dition to total bone formation and histology, the CFMD
model provides an opportunity in one model to assess the
pattern, distribution, and remodeling features associated
with a material in varying biological settings. The PC region
models an environment in which sources of osteogenic cells
are robust and can be derived from periosteum, cortex, or
endosteum, while assessment in the IM region models an
environment in which osteogenic cells are less abundant and
the defect site is bounded by hematopoietic marrow and fat.
These conditions are not as severe as the defect sites that are
the target of treatment, but are clearly challenging enough to
stratify the performance of available scaffold materials and
detect significant differences in performance.
The value of the CFMD model as a tool for evaluation of
bone grafting strategies is not limited to the evaluation of
osteoconductive scaffold materials as presented here. The
CFMD model has been shown to be an effective tool for
comparison of cell sourcing and processing strategies,48 and
methods involving growth factor delivery use.38 The CFMD
model is currently being evaluated for use in assessment of
methods to optimizes the microenvironment for cell trans-
plantation (e.g., the use of platelet gel preparations), and the
selective surface modification of biomaterials (e.g., presen-
tation of tethered growth factors).
The demonstrated utility of the CFMD model does not,
however, displace the value of using smaller animal model
systems in the rat (calvarial or femoral defect) or rabbit
(calvarial or radius defect). In most biomaterial evaluations,
it is most appropriate to prescreen materials for efficacy in
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these smaller and less rigorous models before advancing
scaffolds into more rigorous large animal models.
Despite the limitation in performance of the polymeric
scaffolds in this study, ongoing work in the design and de-
velopment of these and other scaffolds based on degradable
synthetic or natural polymers is well justified. Synthetic poly-
mer scaffolds have potentially large theoretical advantages
over allograft scaffolds. Polymer scaffolds are almost certainly
more reproducible than scaffolds made from allografts that are
derived from highly standardized starting materials. In addi-
tion, several fabrication methods enable polymer scaffolds to be
designed with highly controlled geometric features that might
be customized for specific sites and applications. Polymer
scaffolds also enable systematic and controlled modification of
surface chemistry (e.g., tethered biomolecules), surface texture,
drug delivery kinetics, and other features that are beyond the
scope of control of current allograft processing methods.
Two scaffold constructs, TyrPCPL/TCP and PPF4SLA/
HAPLGA Dip, were found to be significantly better than al-
ternative constructs, both when considering % BV measured
in the overall region of the implant and when considering
just the most biologically challenging center region of the IM
region. While comparable in performance based on % BV
measurements, these two scaffolds differ greatly in substrate
material, structure, surface texture, surface chemistry, and
degradation properties.
PPF4SLA/HAPLGA Dip represents a porous PPF scaffold
that is manufactured using SLA and subsequently spray
coated with PLGA and HA suspended in chloroform. This
provides a highly regular and fully interconnected porous
structure with pore size of 1000 microns and wall thickness
of 500 microns. The walls of the PPF scaffolds are relatively
smooth and are nonporous, providing a modest surface area
on which a coating of HA nanoparticles and PLGA 50:50 was
applied, and on which other bioactive agents or cells might
be presented in the future. (Fig. 2) The PPF4SLA/HAPLGA Dip
is, by design, a very slowly degrading polymer that has
degraded little in the first 4 weeks following implantation in
the CFMD model. This scaffold is also designed to have the
capacity to serve as a structural load bearing or load-sharing
construct in a bone defect site. This is a potentially valuable
attribute in many clinical settings, particularly segmental
bone defects. The mechanical properties of PPF scaffolds
vary depending on resin composition and porosity, but
typically exhibit a compressive strength ranging from 0.4 to
69MPa, and a compressive modulus of 1.5 to 195MPa.23,26,30
In the current model, the capacity to bear load is not a
particular advantage, nor is the limited amount of degrada-
tion, since any part of the defect site that is occupied by
polymer is automatically unavailable for new bone formation.
No accommodation or adjustment was made in the analysis
that is presented here to consider just the % BV of bone formed
within the available porous volume of the total volume of the
PPF4SLA/HAPLGA Dip scaffolds in the 1 cm diameter· 1.5 cm
length of the defect volume in the CFMDmodel. Were such an
adjustment made, the relative volume of bone formed in these
sites would be more than doubled for PPF4SLA/HAPLGA Dip
and other PPF scaffolds. However, this would not significantly
change the relative performance of PPF4SLA/HAPLGA Dip when
compared to either TyrPCPL/TCP or MCA.
The experiments evaluating PPF scaffolds that are described
here allowed two comparisons to be made. In Experiment 4,
PPF substrates with a meanmolecular weight of 2000 and 4000
were compared. The slower degrading PPF4SLA/HAPLGA Dip
performed better based on mean % BV, but the difference was
not statistically different. In Experiment 6, coatings containing
HA+PLGA or TCP+PLGA were compared. There was no
difference in performance and the variance was wider than in
Experiment 4. Further improvement in the performance of PPF
scaffolds is currently focusing on modification of the surface
coating and/or the delivery of local bioactive agents or cells.
For example, Kempen et al. have shown that PPF scaffolds can
be used to deliver BMP-2 or VEGF.24
The evaluations performed with TyrPC-based scaffolds in
these studies have identified parameters that are under ongoing
optimization. In Experiment 2, a benefit was found when cal-
cium mineral was added to a TyPC scaffold fabricated using
3DP. In Experiment 3, a benefit was found in moving from a
3DP fabrication strategy to a PL method. The increase in bone
formation that was seen is possibly due to the highly inter-
connected, bimodal pore structure and higher overall porosity
that results from the PL fabrication process.12 In Experiment 7,
the benefit of adding calcium mineral to PL scaffolds was con-
firmed, using either b-TCP or the highly soluble CaCl2. b-TCP
performedbetter, however, perhapsdue toprolonged residence
within the scaffold.Despite the relatively rapiddegradation that
was designed for this polymer, histological assessment sug-
gested that*30% of the defect site was still occupied by poly-
meric materials after 4 weeks in vivo, and that fibrous tissue
formation was common in regions where fragments of the bulk
polymer were retained. Further modification of structural or
degradation properties, or the composition of calcium contain-
ing agents, may improve the reliability of bone formation.
Finally, in addition to demonstrating that the CFMD model
has substantial value in the assessment of scaffolds and surface
coatings in general, and in determining whether further
changes in the current scaffolds may result in significant im-
provement in performance in particular, these data also point
to a possible ceiling effect limitation in this model with respect
to performance measurement based on mineralization alone as
an estimate of new bone formation. Specifically, the perfor-
mance that has been documented for MCA is likely at or close
to the upper limit of performance that might be expected from
any osteoconductive material in this model when mineraliza-
tion and MicroCT alone are used as the outcome parameter.
As a result, the CFMD model may be insensitive to the de-
tection of further improvements in performance that might be
achieved by combination of MCA with cell therapy ap-
proaches or the delivery of bioactive agents unless MicroCT
data are combined with histology and histomorphometry,
which would allow quantitative assessment of remodeling as
well as bone formation as an outcome metric. As a result, in
order to further advance the performance of MCA or other
allograft constructs combined with other cell sourcing options
or bioactive agents using the CFMDmodel, histomorphometry
will be added as an intrinsic outcome metric. Consideration
can also be made for advancement of high-performing mate-
rials into more stringent models, such as the chronic caprine
tibial defect model that has been recently reported.37
Conclusion
MCA remains the current standard for osteoconductive
scaffolds. The polymer scaffold constructs tested thus far in
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the CFMD model, while conceptually promising, do not
approach the level of performance that is achieved by MCA.
Ongoing work on polymer scaffolds is still justified, how-
ever. The potential for surface modification using variations
of calcium-containing surface coatings and/or the delivery of
BMP-2 to improve the performance of these scaffold con-
structs is currently being tested.
The work in this article further establishes the CFMD
model as a platform of testing methodology and perfor-
mance metrics that can now be used to measure the relative
efficacy of many scaffold materials and surface coatings. This
platform of experience and data further enables the subse-
quent assessment of the added benefit of cell therapy ap-
proaches and bioactive agents (e.g., BMPs) on these or other
bulk scaffold materials.
Ongoing work to further optimize the use of MCA in se-
vere segmental defects will evaluate MCA as a delivery ve-
hicle for osteogenic cell sources and/or in combination with
bioactive adjuvant materials. Future studies will utilize the
CFMD model, but ultimately require the use of the more
stringent models, such as the chronic caprine tibial defect
model that was described above.37
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